15 December 2022 
EMA/CHMP/917134/2022 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Fintepla 
fenfluramine 
On 15 December 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Fintepla. The marketing authorisation holder for this medicinal product is Zogenix ROI Limited. 
The CHMP adopted a new indication to add treatment of seizures associated with Lennox-Gastaut 
syndrome. For information, the full indications will therefore be as follows:2 
Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and 
Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 
2 years of age and older. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
